Goldman Sachs raised the firm’s price target on Boston Scientific (BSX) to $124 from $120 and keeps a Buy rating on the shares. The firm said that, post-Q3 results, it revised its forecasts to reflect the results and updated 2025 guidance for both organic growth and earnings per share; business mix projections; P&L assumptions, and; free cash flow projections. Goldman added that it continues to see the company well-positioned to deliver sales and EPS growth above large cap MedTech peer averages rates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Strong Q3 Performance and WATCHMAN Growth Justify Buy Rating
- Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating
- Boston Scientific’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Boston Scientific price target raised to $113 from $110 at Evercore ISI
- Morning Movers: GE Vernova climbs after third quarter earnings